Pro Medicus (ASX: PME) – Pro Medicus Signs $23M St Luke’s Contract

Henry Fung

Henry is a co-founder of MF & Co. Asset Management with over 20 years in financial services as a trader and investor, including the past 10 years advising clients and building quantitative trading systems. Henry also maintains a high conviction list of 5 stocks that you can get for free and has a free 5-day course on how professionals use quantitative strategies to find an edge. The concepts in the course are applied in the Quantitative Leveraged ETF L/S Strategy.


August 12, 2026

Pro Medicus (ASX: PME)View stock profile →

Pro Medicus Limited has secured a A$23 million, seven-year contract with St. Luke’s Health System, a significant expansion of its footprint in the North American healthcare technology market. The agreement, announced on 12 August 2026, will deploy the company’s cloud-based Visage 7 enterprise imaging platform across one of Idaho’s largest health systems, which operates 10 medical centers spanning southern Idaho, eastern Oregon, and northern Nevada. St. Luke’s is the state’s largest private employer and a not-for-profit healthcare provider, making it a material win for Pro Medicus in the competitive U.S. health IT space.

The contract represents a validation of Pro Medicus’ strategic pivot toward cloud-based medical imaging solutions. St. Luke’s will implement both Visage 7 Viewer and Visage 7 Workflow through the company’s proven cloud deployment process, with implementation planned for Q1 2027. The transaction-based licensing model is particularly noteworthy for investors, as it carries potential revenue upside beyond the headline contract value. This means the actual value to Pro Medicus could exceed the initial A$23 million figure if utilisation rates or ancillary services exceed current projections, providing optionality that pure fixed-fee contracts would not offer.

For investors, this win signals continued momentum in the company’s North American expansion. Pro Medicus CEO Dr Sam Hupert noted that St. Luke’s joins a growing list of large healthcare systems adopting fully cloud-based platforms, a market shift that favours the company’s CloudPACS strategy. The CEO also highlighted a strong pipeline spanning multiple customer segments, from large academic medical centers through mid-sized integrated delivery networks like St. Luke’s to private imaging groups, which collectively represent what the company views as the largest addressable market among competing medical imaging platforms. This diversified pipeline suggests Pro Medicus is well-positioned across multiple customer tiers rather than dependent on any single segment.

The timing matters for healthcare IT investment patterns. Healthcare budgets remain under pressure across the U.S., yet major health systems continue to invest in modernisation and cloud migration. St. Luke’s decision to transition suggests confidence in both the economic case for cloud-based imaging and in Visage 7’s capability to support large, geographically dispersed health networks. A successful implementation at St. Luke’s could serve as a reference site for other similar-sized systems evaluating cloud platforms, potentially accelerating future contract wins.

The scheduled Q1 2027 go-live provides a near-term milestone for the market to monitor. Revenue recognition will likely occur post-deployment, so while the contract was announced in August 2026, material revenue flow depends on successful execution and transaction volumes across St. Luke’s sites. Investors should track the company’s guidance and pipeline commentary to gauge whether the St. Luke’s win is part of a sustained acceleration. This announcement is price sensitive and flagged as material by the ASX.

Our Exclusive Top 5 Stock Picks

Five high conviction stocks that didn't make the public list. Backed by institutional research with significant upside potential. Subscribe for free access.

Invalid email address
By subscribing, you consent to receive communications from us. You can unsubscribe at any time.

View the full ASX announcement (PDF)

About Pro Medicus Limited (ASX: PME)

Pro Medicus Limited is an Australian health imaging software company headquartered in Victoria that develops advanced diagnostic imaging solutions for the global healthcare market. The company’s main business segment centers on its Visage imaging platform, a viewer and analysis solution used by hospitals and medical institutions to manage and interpret medical images. Pro Medicus operates primarily through its U.S. subsidiary Visage Imaging, Inc., serving major healthcare systems across North America and internationally on a transaction-based licensing model.

If you would like to discuss this announcement or how it might affect your portfolio, request a callback or call us on 1300 889 603.

This is general advice only. MF & Co Asset Management has not considered your personal financial needs, objectives or current situation. This information is not an offer, solicitation, or a recommendation for any financial product unless expressly stated. You should seek professional investment advice before making any investment decision.

You May Also Like…

Subscribe

Want more Free Research?

Subscribe today for free and get an alert when we have new research and webinars.

Invalid email address
We promise not to spam you. You can unsubscribe at any time.

MF & Co. Asset Management

MF & Co. Asset Management is a boutique investment firm offering Equity Capital Markets and derivative general advice & trade execution services.

We are specialists in advising and trading in Australian and US Equities, Index & Equity Options and Options on Futures.

Contact

Get In Touch

Australia
1300 889 603
International
+61 2 8378 7199
M-F: 8am-5pm

Suite 803, Level 8
70 Pitt St, Sydney, NSW 2000

 

Share This